Soleno Therapeutics (SLNO) CBO granted RSUs and 4,000 stock options

Rhea-AI Filing Summary

Soleno Therapeutics executive Kevin Norrett reported new equity awards in the form of restricted stock units and stock options. On January 21, 2026, he received 3,500 restricted stock units of Common Stock at no cost, bringing his beneficial ownership to 17,786 RSUs representing shares of Common Stock. These RSUs are scheduled to vest 100% on December 15, 2027, as long as he continues as a service provider under the company’s 2014 Equity Incentive Plan.

On the same date, he was also granted an employee stock option to purchase 4,000 shares of Common Stock at an exercise price of $43.65 per share. This option vests in equal monthly installments, with 1/48th of the shares vesting on February 1, 2026 and on each monthly anniversary thereafter, subject to his continued service. Both awards are standard compensation arrangements that align his interests with long-term company performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Norrett Kevin

(Last) (First) (Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		A		3,500(1)	A	$0	17,786(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$43.65	01/21/2026		A		4,000		(3)	01/21/2036	Common Stock	4,000	$0	4,000	D

Explanation of Responses:

1. These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. 100% of the RSUs shall vest on December 15, 2027, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through such date.

2. These securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

3. 1/48th of the shares subject to the option shall vest on February 1, 2026 and each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each such date.

	/s/ Anish Bhatnagar, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Soleno Therapeutics (SLNO) report for Kevin Norrett?

The Chief Business Officer, Kevin Norrett, reported the grant of 3,500 restricted stock units (RSUs) of Common Stock and an employee stock option for 4,000 shares of Common Stock on January 21, 2026.

How many Soleno Therapeutics (SLNO) shares does Kevin Norrett beneficially own after this Form 4?

Following the reported RSU grant, Kevin Norrett beneficially owns 17,786 RSUs, each representing a contingent right to receive one share of Soleno Therapeutics Common Stock, subject to their respective vesting conditions.

What are the vesting terms of Kevin Norrett’s new RSUs at Soleno Therapeutics (SLNO)?

The 3,500 RSUs granted to Kevin Norrett will vest 100% on December 15, 2027, provided he continues to be a service provider under Soleno Therapeutics’ 2014 Equity Incentive Plan through that date.

What are the key terms of the new employee stock option granted to Kevin Norrett by Soleno Therapeutics (SLNO)?

The employee stock option covers 4,000 shares of Common Stock at an exercise price of $43.65 per share. 1/48th of the shares vest on February 1, 2026, and 1/48th vests on each one-month anniversary thereafter, subject to his continued service.

Did Kevin Norrett pay anything for the RSUs and options reported in this Soleno Therapeutics (SLNO) Form 4?

The 3,500 RSUs were granted at a price of $0. The employee stock option was granted at no cost but has an exercise price of $43.65 per share if and when he chooses to purchase the underlying shares after vesting.

Is the Form 4 for Soleno Therapeutics (SLNO) reporting a stock sale by Kevin Norrett?

No. The Form 4 reports awards granted to Kevin Norrett—RSUs and a stock option—coded as acquisitions. It does not report any sale or disposition of Soleno Therapeutics shares.